David Angulo, MD
Scynexis, Inc.
7
0
5
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Marc Engelhardt
Basilea Pharmaceutica International Ltd, Allschwil
Shared therapeutic areas:
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Shared therapeutic areas:
Jorge Cortes, MD
UT MD Anderson Cancer Center
Shared therapeutic areas:
Sriram Sampath, MD
St John Medical College, Bengaluru
Shared therapeutic areas:
Weili Zhao, PhD
Ruijin Hospital
Shared therapeutic areas:
Arvind Baronia, MD
SGPGI, Lucknow
Shared therapeutic areas:
Anupma J Kindo, MD
Sri Ramchandra Medical University, Chennai
Shared therapeutic areas:
Pradip Bhattacharyya, MD
Chirayu Medical College, Bhopal
Shared therapeutic areas:
Gregory Reid, MSc, MBA
MethylGene Inc.
Shared therapeutic areas:
Saad Nseir, MD,PhD
University Hospital, Lille
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
All 7 trials loaded